The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders

Antony B. Friedman, Miles P. Sparrow, Peter R. Gibson

Research output: Contribution to journalReview ArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Thiopurines have been a cornerstone of medical management of patients with inflammatory bowel disease (IBD) and many rheumatological disorders. The thiopurines are metabolized to their end products, 6-methymercaptopurine (6MMP) and the 6-thioguanine nucleotides (6TGN), with 6TGN being responsible for thiopurine efficacy by causing apoptosis and preventing activation and proliferation of T-lymphocytes. In IBD, conventional weight-based dosing with thiopurines leads to an inadequate response in many patients. Utilizing measurement of these metabolites and then employing dose optimization strategies has led to markedly improved outcomes in IBD. Switching between thiopurines as well as the addition of low-dose allopurinol can overcome adverse events and elevate 6TGN levels into the therapeutic window. There is a paucity of data on thiopurine metabolites in rheumatological diseases and further research is required.

Original languageEnglish
Pages (from-to)132-141
Number of pages10
JournalInternational Journal of Rheumatic Diseases
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • 6-methymercaptopurine
  • 6-thioguanine nucleotide
  • Inflammatory bowel disease
  • Thiopurines

Cite this

@article{108ac6f85d7a43e38f6f55a179dd4fb9,
title = "The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders",
abstract = "Thiopurines have been a cornerstone of medical management of patients with inflammatory bowel disease (IBD) and many rheumatological disorders. The thiopurines are metabolized to their end products, 6-methymercaptopurine (6MMP) and the 6-thioguanine nucleotides (6TGN), with 6TGN being responsible for thiopurine efficacy by causing apoptosis and preventing activation and proliferation of T-lymphocytes. In IBD, conventional weight-based dosing with thiopurines leads to an inadequate response in many patients. Utilizing measurement of these metabolites and then employing dose optimization strategies has led to markedly improved outcomes in IBD. Switching between thiopurines as well as the addition of low-dose allopurinol can overcome adverse events and elevate 6TGN levels into the therapeutic window. There is a paucity of data on thiopurine metabolites in rheumatological diseases and further research is required.",
keywords = "6-methymercaptopurine, 6-thioguanine nucleotide, Inflammatory bowel disease, Thiopurines",
author = "Friedman, {Antony B.} and Sparrow, {Miles P.} and Gibson, {Peter R.}",
year = "2014",
month = "2",
doi = "10.1111/1756-185X.12204",
language = "English",
volume = "17",
pages = "132--141",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "2",

}

The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. / Friedman, Antony B.; Sparrow, Miles P.; Gibson, Peter R.

In: International Journal of Rheumatic Diseases, Vol. 17, No. 2, 02.2014, p. 132-141.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders

AU - Friedman, Antony B.

AU - Sparrow, Miles P.

AU - Gibson, Peter R.

PY - 2014/2

Y1 - 2014/2

N2 - Thiopurines have been a cornerstone of medical management of patients with inflammatory bowel disease (IBD) and many rheumatological disorders. The thiopurines are metabolized to their end products, 6-methymercaptopurine (6MMP) and the 6-thioguanine nucleotides (6TGN), with 6TGN being responsible for thiopurine efficacy by causing apoptosis and preventing activation and proliferation of T-lymphocytes. In IBD, conventional weight-based dosing with thiopurines leads to an inadequate response in many patients. Utilizing measurement of these metabolites and then employing dose optimization strategies has led to markedly improved outcomes in IBD. Switching between thiopurines as well as the addition of low-dose allopurinol can overcome adverse events and elevate 6TGN levels into the therapeutic window. There is a paucity of data on thiopurine metabolites in rheumatological diseases and further research is required.

AB - Thiopurines have been a cornerstone of medical management of patients with inflammatory bowel disease (IBD) and many rheumatological disorders. The thiopurines are metabolized to their end products, 6-methymercaptopurine (6MMP) and the 6-thioguanine nucleotides (6TGN), with 6TGN being responsible for thiopurine efficacy by causing apoptosis and preventing activation and proliferation of T-lymphocytes. In IBD, conventional weight-based dosing with thiopurines leads to an inadequate response in many patients. Utilizing measurement of these metabolites and then employing dose optimization strategies has led to markedly improved outcomes in IBD. Switching between thiopurines as well as the addition of low-dose allopurinol can overcome adverse events and elevate 6TGN levels into the therapeutic window. There is a paucity of data on thiopurine metabolites in rheumatological diseases and further research is required.

KW - 6-methymercaptopurine

KW - 6-thioguanine nucleotide

KW - Inflammatory bowel disease

KW - Thiopurines

UR - http://www.scopus.com/inward/record.url?scp=84896695258&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12204

DO - 10.1111/1756-185X.12204

M3 - Review Article

VL - 17

SP - 132

EP - 141

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 2

ER -